Clearmind Medicine (CMND) announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide, sourced through the Company’s partnership with NeuroThera Labs, with classic and innovative psychedelic compounds. These combinations aim to enhance therapeutic potential while potentially improving safety, tolerability, and neuroplasticity profiles for various mental health and neurological indications.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces Hong Kong patent filing for depression therapy
- Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
- SciSparc’s Neurothera Labs announces publication of international patent
- Clearmind advances recruitment for CMND-100 trial’s third cohort
- Clearmind Medicine announces publication of patent for weight loss therapy